Vadadustat

Last updated

Vadadustat
Vadadustat.svg
Clinical data
Trade names Vafseo
Other namesAKB-6548, PG-1016548
AHFS/Drugs.com Monograph
License data
Pregnancy
category
ATC code
Legal status
Legal status
Identifiers
  • 2-([5-(3-Chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino)acetic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
PDB ligand
CompTox Dashboard (EPA)
ECHA InfoCard 100.248.991 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C14H11ClN2O4
Molar mass 306.70 g·mol−1
3D model (JSmol)
  • Oc1cc(cnc1C(=O)NCC(=O)O)c2cccc(Cl)c2
  • InChI=1S/C14H11ClN2O4/c15-10-3-1-2-8(4-10)9-5-11(18)13(16-6-9)14(21)17-7-12(19)20/h1-6,18H,7H2,(H,17,21)(H,19,20)
  • Key:JGRXMPYUTJLTKT-UHFFFAOYSA-N

Vadadustat, sold under the brand name Vafseo, is a medication used for the treatment of symptomatic anemia associated with chronic kidney disease. [2] [3] Vadadustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor. [2]

Contents

The most common side effects include thromboembolic events (problems due to the formation of blood clots in the blood vessels), diarrhea, and hypertension (high blood pressure). [3]

Vadadustat was approved for medical use in the European Union in April 2023, [3] and in the United States in March 2024. [2] [5] [6]

Medical uses

In the EU, vadadustat is indicated for the treatment of symptomatic anemia associated with chronic kidney disease in adults on chronic maintenance dialysis. [3]

In the US, vadadustat is indicated for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months. [2]

History

The US Food and Drug Administration approved vadadustat based on evidence from two clinical trials, INNO2VATE-1 (NCT02865850) and INNO2VATE-2 (NCT02892149), in which 3,923 adults with anemia due to CKD who have been receiving dialysis for at least three months were equally randomized to receive either vadadustat or darbepoetin alfa. [7] The trials were conducted at 83 sites in one study and 275 sites in another study in a total of 18 countries in North America, South America, Europe, Africa, and Asia, of which 2,361 (60%) participants were from the United States. [7] The same trials were used to evaluate the safety and efficacy of vadadustat. [7] INNO2VATE-1 and INNO2VATE-2 were both global, multi-center, randomized, active-controlled, non-inferiority, open-label trials. [7] Participants in each trial were randomized equally to receive either vadadustat with a starting dose of 300 mg once daily or darbepoetin alfa administered subcutaneously or intravenously as per the prescribing information for 52 weeks to assess the efficacy endpoints. [7] Vadadustat was administered in increments of 150 mg up to 600 mg to achieve the hemoglobin (Hb) target. [7] After 52 weeks, participants continued study medication to assess long-term safety until a major adverse cardiovascular event (MACE) occurred. [7] Efficacy in each study was based on the difference in mean change of Hb from baseline to Weeks 24 to 36 of the trial. [7] An additional efficacy endpoint was the difference in the average change of Hb from baseline to Weeks 40 to 52. [7]

Society and culture

In February 2023, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Vafseo, intended for the treatment of symptomatic anemia in adults with chronic kidney disease who are on chronic dialysis. [8] The applicant for this medicinal product is Akebia Europe Limited. [8] Vadadustat was approved for medical use in the European Union in April 2023. [3] [4]

Research

Vadadustat is in phase III clinical trials for the treatment of anemia caused by chronic kidney disease. [9] [10] [11] [12] [13]

References

  1. 1 2 "Vafseo APMDS". Therapeutic Goods Administration (TGA). 17 October 2023. Archived from the original on 2 January 2024. Retrieved 7 March 2024.
  2. 1 2 3 4 5 "Vafseo- vadadustat tablet, film coated". DailyMed. 27 March 2024. Archived from the original on 25 April 2024. Retrieved 25 April 2024.
  3. 1 2 3 4 5 6 "Vafseo EPAR". European Medicines Agency. 31 May 2023. Archived from the original on 3 June 2023. Retrieved 3 June 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  4. 1 2 "Vafseo Product information". Union Register of medicinal products. 25 April 2023. Retrieved 23 March 2025.
  5. ↑ "Novel Drug Approvals for 2024". U.S. Food and Drug Administration (FDA). 29 April 2024. Archived from the original on 30 April 2024. Retrieved 30 April 2024.
  6. ↑ New Drug Therapy Approvals 2024 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2025. Archived from the original on 21 January 2025. Retrieved 21 January 2025.
  7. 1 2 3 4 5 6 7 8 9 "Drug Trials Snapshots: Vafseo". U.S. Food and Drug Administration. 1 October 2024. Retrieved 23 March 2025.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  8. 1 2 "Vafseo: Pending EC decision". European Medicines Agency (EMA). 24 February 2023. Archived from the original on 25 February 2023. Retrieved 24 February 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  9. ↑ Pergola PE, Spinowitz BS, Hartman CS, Maroni BJ, Haase VH (November 2016). "Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease". Kidney International. 90 (5): 1115–1122. doi: 10.1016/j.kint.2016.07.019 . PMID   27650732.
  10. ↑ Gupta N, Wish JB (June 2017). "Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD". American Journal of Kidney Diseases. 69 (6): 815–826. doi: 10.1053/j.ajkd.2016.12.011 . PMID   28242135.
  11. ↑ Martin ER, Smith MT, Maroni BJ, Zuraw QC, deGoma EM (2017). "Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease". American Journal of Nephrology. 45 (5): 380–388. doi:10.1159/000464476. PMC   5452283 . PMID   28343225.
  12. ↑ Eckardt KU, Agarwal R, Aswad A, Awad A, Block GA, Bacci MR, et al. (April 2021). "Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis". The New England Journal of Medicine. 384 (17): 1601–1612. doi: 10.1056/NEJMoa2025956 . PMID   33913638.
  13. ↑ Chertow GM, Pergola PE, Farag YM, Agarwal R, Arnold S, Bako G, et al. (April 2021). "Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD". The New England Journal of Medicine. 384 (17): 1589–1600. doi: 10.1056/NEJMoa2035938 . PMID   33913637.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.